A randomized, double-blind, placebo-controlled multicenter phase III study comparing denosumab with placebo as adjuvant treatment for women with early-stage breast cancer who are at high risk of disease recurrence (D-CARE).

Abstract OT2-3-03: Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer at high risk of disease recurrence (D-CARE): An international, randomized, double-blind, placebo-controlled phase 3 clinical trial

10.1158/0008-5472.sabcs12-ot2-3-03 ◽

2012 ◽

Cited By ~ 1

Author(s):

PE Goss ◽

CH Barrios ◽

A Chan ◽

DM Finkelstein ◽

H Iwata ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

High Risk ◽

Adjuvant Treatment ◽

Early Stage ◽

Disease Recurrence ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

OT1-01-03: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter Study Comparing Denosumab with Placebo as Adjuvant Treatment for Women with Early-Stage Breast Cancer Who Are at High Risk of Disease Recurrence (D-CARE).

10.1158/0008-5472.sabcs11-ot1-01-03 ◽

2011 ◽

Author(s):

PE Goss ◽

CH Barrios ◽

R Bell ◽

D Finkelstein ◽

H Iwata ◽

...

Keyword(s):

Breast Cancer ◽

High Risk ◽

Adjuvant Treatment ◽

Multicenter Study ◽

Early Stage ◽

Disease Recurrence ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2−breast cancer

Annals of Oncology ◽

10.1093/annonc/mdz416.023 ◽

2019 ◽

Vol 30 ◽

pp. ix7-ix8

Author(s):

F. Cardoso ◽

A. Bardia ◽

F. André ◽

D.W. Cescon ◽

H. McArthur ◽

...

Keyword(s):

Breast Cancer ◽

High Risk ◽

Neoadjuvant Chemotherapy ◽

Endocrine Therapy ◽

Early Stage ◽

Adjuvant Endocrine Therapy ◽

Phase Iii ◽

Double Blind ◽

Her2 Breast Cancer ◽

Abstract OT3-04-03: KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab versus placebo in combination with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk early-stage ER+/HER2–breast cancer

10.1158/1538-7445.sabcs18-ot3-04-03 ◽

2019 ◽

Author(s):

F Cardoso ◽

A Bardia ◽

F Andre ◽

DW Cescon ◽

H McArthur ◽

...

Keyword(s):

Breast Cancer ◽

High Risk ◽

Neoadjuvant Chemotherapy ◽

Endocrine Therapy ◽

Early Stage ◽

Adjuvant Endocrine Therapy ◽

Phase Iii ◽

Double Blind ◽

Her2 Breast Cancer ◽

Abstract OT2-6-02: Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer at high risk of disease recurrence (D-CARE): A global, placebo-controlled, randomized, double-blind, phase 3 clinical trial

10.1158/0008-5472.sabcs13-ot2-6-02 ◽

2013 ◽

Cited By ~ 1

Author(s):

PE Goss ◽

CH Barrios ◽

A Chan ◽

DM Finkelstein ◽

H Iwata ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

High Risk ◽

Adjuvant Treatment ◽

Early Stage ◽

Disease Recurrence ◽

Early Stage Breast Cancer ◽

Phase 3 ◽

Double Blind ◽

Cardiac Tolerability of Pertuzumab Plus Trastuzumab Plus Docetaxel in Patients With HER2‐Positive Metastatic Breast Cancer in CLEOPATRA: A Randomized, Double‐Blind, Placebo‐Controlled Phase III Study

The Oncologist ◽

10.1634/theoncologist.2012-0448 ◽

2013 ◽

Vol 18 (3) ◽

pp. 257-264 ◽

Cited By ~ 86

Author(s):

Sandra M. Swain ◽

Michael S. Ewer ◽

Javier Cortés ◽

Dino Amadori ◽

David Miles ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

Her2 Positive ◽

Double Blind ◽

Double Blind Placebo ◽

Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO.

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.lba1011 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. LBA1011-LBA1011 ◽

Cited By ~ 87

Author(s):

D. Miles ◽

A. Chan ◽

G. Romieu ◽

L. Y. Dirix ◽

J. Cortes ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Double Blind ◽

Double Blind Placebo ◽

First Line Therapy ◽

Line Therapy ◽

Phase Iii Study ◽

Locally Recurrent

Abstract P5-18-26: Confirmatory overall survival (OS) analysis of CLEOPATRA: a randomized, double-blind, placebo-controlled Phase III study with pertuzumab (P), trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive first-line (1L) metastatic breast cancer (MBC)

10.1158/0008-5472.sabcs12-p5-18-26 ◽

2012 ◽

Cited By ~ 5

Author(s):

SM Swain ◽

S-B Kim ◽

J Cortes ◽

J Ro ◽

V Semiglazov ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Her2 Positive ◽

Double Blind ◽

Double Blind Placebo ◽

Abstract GS1-04: IMpassion130: Efficacy in immune biomarker subgroups from the global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab +nab-paclitaxel in patients with treatment-naïve, locally advanced or metastatic triple-negative breast cancer

10.1158/1538-7445.sabcs18-gs1-04 ◽

2019 ◽

Cited By ~ 24

Author(s):

LA Emens ◽

S Loi ◽

HS Rugo ◽

A Schneeweiss ◽

V Diéras ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Locally Advanced ◽

Phase Iii ◽

Double Blind ◽

Double Blind Placebo ◽

Treatment Naïve ◽

Abstract OT1-08-03: Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of adagloxad simolenin (OBI-822) and OBI-821 treatment in patients with early-stage triple-negative breast cancer (TNBC) at high risk for recurrence

10.1158/1538-7445.sabcs19-ot1-08-03 ◽

2020 ◽

Cited By ~ 1

Author(s):

Hope S Rugo ◽

Louis WC Chow ◽

Javier Cortes ◽

Peter A Fasching ◽

Binghe Xu ◽

...

Keyword(s):

Breast Cancer ◽

High Risk ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Early Stage ◽

Controlled Study ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo